3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
3
Unknown
2
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Neoplasm Metastasis
5
Colorectal Neoplasms
4
Solid Tumor
3
Stomach Neoplasms
2
Melanoma
2
Endometrial Neoplasms
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Metastatic Solid Tumors
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma
1
Extensive Stage Small Cell Lung Cancer
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colonic Neoplasms
1
Breast Neoplasms
1
Advanced Solid Tumors
1
Adenocarcinoma
1
Interventions
Gemcitabine
34
pembrolizumab
27
Paclitaxel
21
Cyclophosphamide
21
Docetaxel
20
Carboplatin
20
Irinotecan
19
Capecitabine
19
Fluorouracil
17
Bevacizumab
15
Dexamethasone
14
fludarabine
13
Oxaliplatin
13
Leucovorin
13
Blood Specimen Collection
13
Everolimus
12
Cetuximab
12
Ipilimumab
11
Erlotinib Hydrochloride
11
Rituximab
10
Pemetrexed
10
Cisplatin
10
venetoclax
9
Temozolomide
9
Sunitinib
9
Nivolumab
9
Trastuzumab
8
Interleukin-2
8
aldesleukin
7
Epoetin Alfa
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms
×
tislelizumab
×
Clear all
NCT04363801
2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2
Terminated
247 enrolled
38 charts